Non-alcoholic Fatty Liver Disease in Africa: a Hidden Danger

Overview

Journal Glob Health Epidemiol Genom

Specialties General Medicine
Public Health

Date 2019 Apr 26

PMID 31019719

Citations 10

Authors

Imran M Paruk

Fraser J Pirie

Ayesha A Motala

Affiliations

Soon will be listed here.

Abstract

There is a dearth of data on the burden and spectrum of non-alcoholic fatty liver disease (NAFLD) in African populations. The limited available information suggests that the prevalence of NAFLD in the general population is lowest for the Africa region. However, this is likely to be an underestimate and also does not take into consideration the long-term impact of rising rates of obesity, type-2 diabetes mellitus (T2DM) and high human immunodeficiency virus infection burden in Africa. A racial disparity in the prevalence of NAFLD has been observed in some studies but remains unexplained. There is an absence of data from population-based studies in Africa and this highlights the need for such studies, to reliably define the health service needs for this region. Screening for NAFLD at a population-based level using ultrasound is perhaps the ideal method for resource-poor settings because of its relative cost-effectiveness. What is required as a priority from Africa, are well-designed epidemiologic studies that screen for NAFLD in the general population as well as high-risk groups such as patients with T2DM or obesity.

Citing Articles

NON-ALCOHOLIC FATTY LIVER DISEASE AND RELATIONSHIP WITH ADIPOSITY IN NIGERIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE IBADAN EXPERIENCE.

Aransiola C, Balogun W Ann Ib Postgrad Med. 2025; 22(2):74-80.

PMID: 40007722 PMC: 11848379.

Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross-Sectional Study.

Napon-Zongo D, Diendere J, Sanou A, Coulibaly A, Dera A, Ouattara N JGH Open. 2024; 8(12):e70069.

PMID: 39655240 PMC: 11626251. DOI: 10.1002/jgh3.70069.

Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients.

Bockarie A, Nartey Y, Nsiah P, Edzie E, Tuoyire D, Acquah S Endocrinol Diabetes Metab. 2023; 6(6):e456.

PMID: 37814510 PMC: 10638625. DOI: 10.1002/edm2.456.

Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Persons with Type 2 Diabetes Mellitus in Ghana: A Study of Prevalence, Severity, and Contributing Factors Using Transient Elastography.

Wiafe Y, Afihene M, Anto E, Nmai R, Amoah-Kumi L, Frimpong J J Clin Med. 2023; 12(11).

PMID: 37297935 PMC: 10253760. DOI: 10.3390/jcm12113741.

Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data.

Riches N, Vinikoor M, Guingane A, Johannessen A, Lemoine M, Matthews P Epidemiol Infect. 2023; 151:e65.

PMID: 37009881 PMC: 10204139. DOI: 10.1017/S095026882300050X.

References

Almobarak A, Barakat S, Khalifa M, Elhoweris M, Elhassan T, Ahmed M . Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors?. Arab J Gastroenterol. 2014; 15(1):12-5. DOI: 10.1016/j.ajg.2014.01.008. View

Almobarak A, Barakat S, Suliman E, Elmadhoun W, Mohamed N, Abobaker I . Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?. Arab J Gastroenterol. 2015; 16(2):54-8. DOI: 10.1016/j.ajg.2015.06.001. View

Amiri Dash Atan N, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R . Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018; 10(Suppl1):S1-S7. PMC: 5838173. View

Marrero J, Fontana R, Su G, Conjeevaram H, Emick D, Lok A . NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002; 36(6):1349-54. DOI: 10.1053/jhep.2002.36939. View

Bohte A, van Werven J, Bipat S, Stoker J . The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2010; 21(1):87-97. PMC: 2995875. DOI: 10.1007/s00330-010-1905-5. View

Frayn K . Adipose tissue as a buffer for daily lipid flux. Diabetologia. 2002; 45(9):1201-10. DOI: 10.1007/s00125-002-0873-y. View

Younossi Z, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B . Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012; 91(6):319-327. DOI: 10.1097/MD.0b013e3182779d49. View

Onyekwere C, Ogbera A, Balogun B . Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. Ann Hepatol. 2011; 10(2):119-24. View

Lesi O, Soyebi K, Eboh C . Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc. 2009; 101(2):151-5. DOI: 10.1016/s0027-9684(15)30828-2. View

10.

Ryan M, Wilson A, Slavin J, Best J, Jenkins A, Desmond P . Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2005; 28(5):1222-4. DOI: 10.2337/diacare.28.5.1222. View

11.

Neuschwander-Tetri B . Non-alcoholic fatty liver disease. BMC Med. 2017; 15(1):45. PMC: 5330146. DOI: 10.1186/s12916-017-0806-8. View

12.

Ioannou G, Boyko E, Lee S . The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006; 101(1):76-82. DOI: 10.1111/j.1572-0241.2005.00341.x. View

13.

Pang Q, Zhang J, Song S, Qu K, Xu X, Liu S . Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol. 2015; 21(5):1650-62. PMC: 4316109. DOI: 10.3748/wjg.v21.i5.1650. View

14.

Afolabi B, Ibitoye B, Ikem R, Omisore A, Idowu B, Soyoye D . The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients. J Natl Med Assoc. 2018; 110(3):256-264. DOI: 10.1016/j.jnma.2017.06.001. View

15.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

16.

Maurice J, Patel A, Scott A, Patel K, Thursz M, Lemoine M . Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017; 31(11):1621-1632. DOI: 10.1097/QAD.0000000000001504. View

17.

Tapper E, Loomba R . Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol. 2018; 15(5):274-282. PMC: 7504909. DOI: 10.1038/nrgastro.2018.10. View

18.

Naran N, Haagensen M, Crowther N . Steatosis in South African women: How much and why?. PLoS One. 2018; 13(1):e0191388. PMC: 5774768. DOI: 10.1371/journal.pone.0191388. View

19.

Kruger F, Daniels C, Kidd M, Swart G, Brundyn K, Van Rensburg C . Non-alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis. S Afr Med J. 2010; 100(3):168-71. DOI: 10.7196/samj.1422. View

20.

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View